千王之王重出江湖

China AI-generated actress’s contact lens ad pulled after netizen backlash its credibility_我的网站

A |     

    The previous snapshot of the "Fang Taozi" account that released a video promoting its colored contact lenses Photo: Sina WeiboA promotion video featuring Chinese virtual actress generated by artificial intelligence (AI) for colored contact lenses has been removed from her short video account after drawing backlash over the credibility of a virtual character claiming real-world comfort of a product.
The AI persona, Fang Taozi, rose to fame as the female lead in hit short drama The Laid-off Girl, which has garnered more than 200 million views. 
In the now-removed ad, Fang said the lenses were "comfortable to wear all day" and the product used a technique to keep them stable, urging users to "blink with confidence," China Youth Daily reported on Sunday.
The claims drew fierce backlash from Chinese netizens, who argued the virtual AI figure cannot wear contact lenses, making its "personal claim of comfort" entirely "uncredible and misleading to consumers." The video is no longer searchable on her page, and her agency did not immediately comment, according to the report.
Lawyers said colored contact lenses are regulated as Class III medical devices in China. The country's Advertising Law prohibits using a spokesperson to recommend or certify medical devices, and such ads must undergo review before publication.
The Advertising Law actually stipulated that a brand ambassador must personally try the product first before endorsing it in an ad. 
Wu Xiaolin, a Beijing-based lawyer, told the Global Times that under the law, an advertising endorser is defined as a natural person, legal entity or other organization making a recommendation in its own name or image. 
"AI digital humans do not have independent legal personality and cannot be advertising endorsers," Wu said, adding that advertisers still bear responsibility for the truthfulness of content and may face penalties for false advertising.
While AI digital avatars are not bound by the legal clauses governing human endorsers, Wu stressed that the ad's firsthand usage experience claims constitute alleged false promotion. Relevant legal liabilities for false advertising will fall on the brand advertiser and the campaign operator rather than the AI avatar itself.
Shanghai-based outlet The Paper reported that Fang's first commercial deal on July 31 listed rates as high as 258,000 yuan ($38,236) for videos exceeding 60 seconds, outstripping many human influencers with millions of followers. An MCN agency source later cast doubt on those figures, saying the actual rate was about 88,000 yuan.
A Global Times reporter noticed that the rise of AI short drama commercial endorsements has become a prevalent industry trend in China, with virtual leads of multiple popular short dramas regularly posting sponsored content for beauty, skincare, beverage and other consumer brands.
Feng Anrong, a director who runs an AI production studio, told the Global Times that commercial endorsements have become a major revenue source for many short drama production teams.
As AI-generated marketing expands, the controversy has exposed a grey area with legal provisions in place and regulatory oversight inadequate. A consumer hotline told local media that the matter has been referred to market regulators in the local district for handling, per China Youth Daily.
。    　　8月26日，多重利好加持，港股通创新药强劲续涨！100%创新药研发标的——港股通创新药ETF华宝（520880）放量连阳。成份股康希诺生物领涨25.99%，信达生物收涨9.69%，股价创历史新高，康方生物涨近6%，百济神州、中国生物制药涨超2%。

B | 　　消息面，创新药迎密集催化！　　1、创新药龙头信达生物中报业绩超预期。上半年产品收入达82.02亿元（同比+56.7%），带动Non-IFRS净利润实现17.04亿元（同比+40.5%）。

C | 管理层首次披露2030年350–400亿元总营收蓝图，剑指全球化全价值链药企。　　2、康希诺生物与德普世生物达成mRNA治疗型肿瘤疫苗战略合作。25日，两家公司正式签署《mRNA个性化治疗型肿瘤疫苗共同开发战略合作框架协议》，共同推进mRNA个性化治疗型肿瘤疫苗的研发与商业化。　　3、政策继续支持创新药高质量发展。《国民健康“十五五”规划》、《全民医疗保障“十五五”规划》近期相继发布，全链条创新药械支持体系持续完善。万联证券指出，后续“基本医保目录+创新药专项目录+商业健康险目录”三层支付体系逐步形成，创新药企和CX0赛道有望受益支付端扩容。　　创新药行情能走多远，当前阶段是否加大关注度？　　华创医药团队认为，近年创新药产业持续向好，销售金额逐年增长，出海数量、出海质量不断提升，坚实的产业基本面是板块股价乐观的核心支撑。

D | 当前创新药板块受量化交易、各类市场叙事影响，呈现高波动态势，但长期向好的产业趋势确定性较强，具备较高长期投资价值，建议对板块保持乐观态度。　　全链布局创新药，关注两大T+0利器：　　港股通创新药ETF华宝（520880）：被动跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，7成仓位押注研发龙头。场外联接基金：025221。　　港股通医疗ETF华宝（159137）：被动跟踪港股通医疗主题指数，重仓创新药产业链，50%CXO+20%创新药，其中药明系占比超38%。场外联接基金：026922。

E | 　　数据来源于沪港深交易所、中证指数公司、恒生指数公司等公开信息。权重数据截至2026.8.25。

F | 　　机构观点参考：万联证券20260824《医药生物行业快评报告：全民医疗保障“十五五”规划发布，关注创新药、康复、医疗信息化赛道机会》。华创证券20260825《华创医药·深度早班车|创新药中期观点汇报》　　注：ETF基金不收取销售服务费。投资者在申购或赎回基金份额时，申购赎回代理券商可按照不超过0.5%的标准收取佣金，其中包含证券交易所、登记机构等收取的相关费用。基金费率详见各基金法律文件。

G | 　　风险提示：文中指数成份股仅作展示，个股描述不作为任何形式的投资建议，也不代表管理人旗下任何基金的持仓信息和交易动向。文中提及个股在恒生港股通创新药精选指数中的权重占比情况：信达生物权重11.42%、康方生物7.51%、康希诺生物0.39%、百济神州 11.90%、石药集团 10.49%、中国生物制药 8.00%。基金管理人评估的港股通医疗ETF华宝、港股通创新药ETF华宝及其联接基金的风险等级为R4-中高风险，适宜积极型（C4）及以上的投资者。任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，投资人须对任何自主决定的投资行为负责。另，本文中的任何观点、分析及预测不构成对阅读者任何形式的投资建议，亦不对因使用本文内容所引发的直接或间接损失负任何责任。基金管理人管理的其他基金的业绩并不构成基金业绩表现的保证，基金的过往业绩并不代表其未来表现，基金投资有风险。责任编辑：杨红卜。

Current article:http://urv.feizengbubaipeirangnalouchuo.sbs/j1g05v/motwy4.html

Published on:00:34:53